Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Glaxosmithkline Plc LSE:GSK London Ordinary Share GB0009252882 ORD 25P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  17.60 1.32% 1,347.80 1,349.20 1,349.80 1,351.00 1,325.80 1,326.80 9,906,187 16:35:18
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 33,754.0 6,221.0 93.9 14.4 67,809

Vir Shares Down 29% After Update on NIH-Sponsored Trial

03/03/2021 8:32pm

Dow Jones News


Glaxosmithkline (LSE:GSK)
Historical Stock Chart


From Feb 2021 to May 2021

Click Here for more Glaxosmithkline Charts.

By Michael Dabaie

 

Vir Biotechnology Inc. shares were down 29% to $40.85 in afternoon trading.

Vir and GlaxoSmithKline PLC said earlier Wednesday the independent data and safety monitoring board recommended the VIR-7831 arm of the National Institutes of Health's Accelerating Covid-19 Therapeutic Interventions and Vaccines Program Phase 3 clinical trial be closed to enrollment.

The companies said they were informed that while VIR-7831 met initial pre-specified criteria to continue to the next phase of the ACTIV-3 trial and there were no reported safety signals, sensitivity analyses of the available data raised concerns about the magnitude of potential benefit.

The monitoring board recommended the VIR-7831 arm of the trial be closed to enrollment while the data mature, the companies said.

The companies said they would continue discussions with the NIH about appropriate ways to further assess the potential of VIR-7831 in the hospitalized population as all parties gain a fuller understanding of the still-emerging data.

The DSMB recommendation was based on a routine, pre-planned safety and efficacy data review of the first 300 patients hospitalized with Covid-19 enrolled in ACTIV-3.

"While we are disappointed with the recommendation of the DSMB, we are encouraged by the safety profile of VIR-7831 and by the possibility of a benefit on top of remdesivir and corticosteroids in this advanced cohort of patients," said Vir Chief Executive George Scangos.

 

Write to Michael Dabaie at michael.dabaie@wsj.com

 

(END) Dow Jones Newswires

March 03, 2021 15:17 ET (20:17 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.

1 Year Glaxosmithkline Chart

1 Year Glaxosmithkline Chart

1 Month Glaxosmithkline Chart

1 Month Glaxosmithkline Chart
ADVFN Advertorial
Your Recent History
LSE
GSK
Glaxosmith..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:gb D:20210512 16:55:28